脑内 CAR-T 细胞递送至胶质母细胞瘤患者。
Intracranial CAR-T cell delivery in glioblastoma patients.
机构信息
Department of Pathology and Laboratory Medicine, Legoretta Cancer Center, Brown University, Providence, RI 02903, USA.
Division of Hematology/Oncology, Lifespan Cancer Institute, Legoretta Cancer Center, Brown University, Providence, RI 02903, USA.
出版信息
Trends Cancer. 2024 Jun;10(6):478-480. doi: 10.1016/j.trecan.2024.05.002. Epub 2024 May 22.
Chimeric antigen receptor (CAR)-T cell therapy is emerging as a promising approach for improving outcomes in high-grade glioma. Here, we highlight three recent studies that reported safety and feasibility of intracranial CAR-T cell administration in patients with glioblastoma (GBM) as well as preliminary evidence of potential responses, supporting further investigations of this approach.
嵌合抗原受体 (CAR)-T 细胞疗法作为一种有前途的方法，正在改善高级别脑胶质瘤的治疗效果。在这里，我们重点介绍了三项最近的研究，这些研究报告了颅内 CAR-T 细胞给药在胶质母细胞瘤（GBM）患者中的安全性和可行性，以及潜在反应的初步证据，为进一步研究这种方法提供了支持。
Zotero 插件